← All trials
NCT05880849
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 26, 2023
- Primary completion
- Jun 30, 2025
- Completion date
- Jun 30, 2026
- First posted
- May 30, 2023
- Last posted
- Oct 13, 2023
- Enrollment
- 14
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Texas at HoustonLead sponsor
- Balchem CorporationCollaborator
- Massachusetts Institute of TechnologyCollaborator
- University of Texas at HoustonCollaborator
- University of Texas at HoustonSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.